Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
Status: | Completed |
---|---|
Conditions: | Neurology, Epilepsy |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 16 - Any |
Updated: | 7/13/2018 |
Start Date: | July 2012 |
End Date: | November 2013 |
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in subjects
with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side
effects; as well as the efficacy, safety and tolerability of BRV. No statistical hypothesis
testing will be performed.
with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side
effects; as well as the efficacy, safety and tolerability of BRV. No statistical hypothesis
testing will be performed.
Inclusion Criteria:
- Subject with well-characterized Epilepsy according to the 1989 International League
Against Epilepsy (ILAE) classification
- Subject with Epilepsy who the investigator expects will benefit from Levetiracetam
(LEV) but for whom the investigator has decided to discontinue due to nonpsychotic
behavioral side effects following the introduction of LEV
- Subject is currently receiving LEV at the recommended therapeutic dose (dose ranging
from 1 g/day to 3 g/day)
- Subject currently treated with minimum 2 and maximum 3 Anti-Epileptic Drugs (AEDs)
including LEV. Vagal Nerve Stimulation (VNS) is allowed and will be counted as a
concomitant AED
- Female subjects without childbearing potential (postmenopausal for at least 2 years,
bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female
subjects with childbearing potential are eligible if they use a medically accepted
contraceptive method
Exclusion Criteria:
- Subject has a lifetime history of suicide attempt (including an actual, interrupted or
aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a
positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide
Severity Rating Scale (C-SSRS) at Visit 1
- Subject whose seizures could not be reliably counted on a regular basis due to their
fast and repetitive occurrence (clusters or flurries)
- Subject has history or presence of status epilepticus during the year preceding Visit
1 or during Baseline
- Subject has history or presence of known psychogenic nonepileptic seizures
- Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic
disease, and/or severe renal impairment) which impair reliable participation in the
study or necessitate the use of medication not allowed by protocol
- Subject is pregnant or lactating
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials